文献速递妇科

初次肿瘤细胞减灭术联合肠切除术后腹腔化疗启动时机对晚期卵巢癌患者结局的影响

Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
PubMed 文献 · Gynecol Oncol · 2020-06-16

这项多中心回顾性队列研究纳入131例晚期卵巢癌行初次肿瘤细胞减灭术联合肠切除后接受腹腔化疗的患者,比较首周期即腹腔化疗与先静脉化疗后转腹腔化疗者,发现前者术后并发症未增加;术中置入腹腔端口可能与大并发症小幅增加相关。

要点

  • 首周期即腹腔化疗者与先静脉化疗者相比,腹腔感染、端口相关并发症及吻合口漏风险均无显著差异。
  • 术中置入腹腔端口者吻合口漏、腹腔感染及端口相关并发症数值上高于术后延迟置入者,但均未达统计学显著。
  • 多数患者为III/IV期(87%)及高级别浆液性组织学(91.6%)。

核心结论

  • 肠切除术后第一辅助化疗周期即给予腹腔化疗,与晚期卵巢癌初次肿瘤细胞减灭术患者术后并发症增加无关。
  • 术中置入腹腔端口可能与该人群主要并发症小幅增加相关。

研究设计与样本

  • 多中心回顾性队列研究,在2个高容量癌症中心开展,共纳入131例晚期卵巢癌行初次肿瘤细胞减灭术联合肠切除后接受腹腔化疗的患者。
  • 75例在首次辅助化疗即开始腹腔化疗,56例先接受静脉化疗后转为腹腔化疗。

主要发现

  • 首周期即腹腔化疗组与先静脉化疗组相比,腹腔感染发生率8% vs 16%(p=0.15),腹腔端口相关并发症20% vs 19.6%(p=0.96),吻合口漏2.7% vs 3.6%(p=0.8),均无显著差异。
  • 术中置入腹腔端口组与术后延迟置入组相比,吻合口漏5.6% vs 3.3%(p=0.62),腹腔感染16.7% vs 6.7%(p=0.17),端口相关并发症24.1% vs 13.3%(p=0.21),差异均未达统计学显著。
  • 87%的患者为III/IV期疾病,91.6%为高级别浆液性组织学。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The primary objective of this study is to determine if early administration of intraperitoneal (IP) chemotherapy and intra-operative insertion of an IP port are associated with increased complications in patients who undergo a bowel resection procedure as part of primary cytoreductive surgery for ovarian cancer. METHODS: This was a multi-centre retrospective cohort study, at 2 high volume cancer centers. For our primary outcomes, univariate logistic regression was completed to assess the impact of timing of IP chemotherapy administration and IP port insertion on perioperative complications. Kaplan Meier survival curves were compared using the Log-Rank test. RESULTS: We identified 131 patients treated with IP chemotherapy after bowel resection during primary cytoreduction for advanced ovarian cancer; 75 patients started IP treatment at the first adjuvant chemotherapy, while 56 patients received intravenous (IV) chemotherapy and later transitioned to IP chemotherapy. The majority of patients had stage III/IV disease (87%) and high-grade serous histology (91.6%). Compared to patients who received their first cycle of chemotherapy IV, patients who started with IP chemotherapy were not at increased risk of intra-abdominal infections (8% vs 16% (p = 0.15)), IP port related complications (20% vs 19.6% (p = 0.96)), or anastomotic leak (2.7% vs 3.6% (p = 0.8)). There was a non-statistically significant trend for increased rates of anastomotic leak (5.6% vs 3.3% (p = 0.62)), intra-abdominal infection (16.7% vs 6.7% (p = 0.17)) and IP port related complications (24.1% vs 13.3% (p = 0.21)) in patients who had intra-operative IP port insertion compared to delayed post-operative port insertion. CONCLUSIONS: Administration of IP chemotherapy in the first post-operative cycle after bowel resection is not associated with increased post-operative complications in women with advanced ovarian carcinoma undergoing primary cytoreductive surgery. Intra-operative IP port insertion may be associated with a small increase in major complications in this population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nica A, Covens A, Parra-Herran C, et al. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer? Gynecol Oncol. 2020. PMID: 32561124. doi:10.1016/j.ygyno.2020.06.478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。